Document is current
Any future updates will be listed below
-
Authors
Løppke, Caroline
Ugleholdt, Randi
Secher, Christine F.
Sand, Nicolai T.
Mujollari, Joana
Gustavsson, Tobias
Dagil, Robert
Theander, Thor G.
Salanti, Ali
Rohrberg, Kristoffer S.
Agerbæk, Mette Ø.
-
Funding
Funding for this research was provided by:
Innovationsfonden (9090-00024B, 9090-00024B, 9090-00024B, 9090-00024B, 9090-00024B)
Novo Nordisk Fonden (NNF21OC0068192, NNF22OC007605, NNF21OC0068192, NNF19OC0058387)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 5 May 2025
First Online: 16 May 2025
Competing interests
: The technology to diagnose cancer through rVAR2 is owned by VarCT Diagnostics through a license from VAR2Pharmaceuticals. A.S., M.Ø.A., and T.G.T. are cofounders of VAR2Pharmaceuticals. The remaining authors declare no competing interests.
